Drug General Information (ID: DDIC1V9D5U)
  Drug Name Carteolol (ophthalmic) Drug Info Levamlodipine Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Antihypertensives Agent
  Structure

 Mechanism of Carteolol (ophthalmic)-Levamlodipine Interaction (Severity Level: Moderate)
     Increased risk of cardiac depression Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Carteolol (ophthalmic) Levamlodipine
      Mechanism Cardiac depressant effects Cardiac depressant effects
      Key Mechanism Factor 1
Factor Name Cardiac depression
Factor Description Cardiac depression may manifest as negative heart rate, negative conduction, and negative contractility. Symptoms include: excessive or more than normal sleep, irritability, loss of interest in activities, and fatigue.
      Mechanism Description
  • Increased risk of cardiac depression by the combination of Carteolol (ophthalmic) and Levamlodipine 

Recommended Action
      Management Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.

References
1 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
2 Pouleur H, Etienne J, Van Mechelen H, et al "Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease." Postgrad Med J 60 (1984): 23-8. [PMID: 6527976]
3 Strauss WE, Egan T, McIntyre KM, Parisi AF "Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure." Clin Cardiol 8 (1985): 363-6. [PMID: 4006348]